Date:\_March 2<sup>nd</sup> 2021

Your Name: João Periquito

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | none   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | none   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | none   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | none   |   |

| 5  | Payment or honoraria for                             | none |  |
|----|--|------|--|
|    | lectures, presentations,                             |      |  |
|    | speakers bureaus,                                    |      |  |
|    | manuscript writing or                                |      |  |
|    | educational events                                   |      |  |
| 6  | Payment for expert                                   | none |  |
|    | testimony  |      |  |
| 7  | Support for attending<br>meetings and/or travel      | none |  |
|    |  |      |  |
|    |  |      |  |
| 8  | Patents planned, issued or                           | none |  |
|    | pending  |      |  |
|    |  |      |  |
| 9  | Participation on a Data                              | none |  |
|    | Safety Monitoring Board or                           |      |  |
|    | Advisory Board                                       |      |  |
| 10 |  | none |  |
|    | in other board, society,                             |      |  |
|    | committee or advocacy                                |      |  |
|    | group, paid or unpaid                                |      |  |
| 11 | Stock or stock options                               | none |  |
|    |  |      |  |
| 12 | Dessist of a subsequent                              |      |  |
| 12 | Receipt of equipment,                                | none |  |
|    | materials, drugs, medical<br>writing, gifts or other |      |  |
|    | services   |      |  |
| 13 | Other financial or non-                              | none |  |
|    | financial interests                                  |      |  |
|    |  |      |  |

Joo Perioputto

X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:\_March 2<sup>nd</sup> 2021

Your Name:\_Thomas Gladytz\_\_\_

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | DFG   | Funding through the collab. research center SFB 1365                                      |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | XNone   |   |
| 3 | Royalties or licenses  | XNone   |   |
| 4 | Consulting fees  | XNone   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events<br>Payment for expert<br>testimony | XNone<br>XNone |  |
|----|---|----------------|--|
| 7  | Support for attending meetings and/or travel  | XNone          |  |
| 8  | Patents planned, issued or<br>pending   | XNone          |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board   | XNone          |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid  | XNone          |  |
| 11 | Stock or stock options  | XNone          |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services   | XNone          |  |
| 13 | Other financial or non-<br>financial interests  | XNone          |  |

Grant funding provided by the German Research Foundation (DFG, Project number 394046635, SFB 1365, RENOPROTECTION).

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

\_\_\_\_ reprint that I have form.

Date:\_March 2<sup>nd</sup> 2021

Your Name: Jason Millward

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | none   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | none   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | none   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | none   |   |

| 5  | Payment or honoraria for                          | none |  |
|----|---|------|--|
|    | lectures, presentations,                          |      |  |
|    | speakers bureaus,<br>manuscript writing or        |      |  |
|    | educational events                                |      |  |
| 6  | Payment for expert                                | none |  |
|    | testimony   |      |  |
|    |   |      |  |
| 7  | Support for attending                             | none |  |
|    | meetings and/or travel                            |      |  |
|    |   |      |  |
|    |   |      |  |
| 8  | Patents planned, issued or                        | none |  |
|    | pending   |      |  |
|    |   |      |  |
| 9  | Participation on a Data                           | none |  |
|    | Safety Monitoring Board or                        |      |  |
|    | Advisory Board                                    |      |  |
| 10 | , ,   | none |  |
|    | in other board, society,<br>committee or advocacy |      |  |
|    | group, paid or unpaid                             |      |  |
| 11 | Stock or stock options                            | none |  |
|    |   |      |  |
|    |   |      |  |
| 12 | Receipt of equipment,                             | none |  |
|    | materials, drugs, medical                         |      |  |
|    | writing, gifts or other<br>services               |      |  |
| 13 | Other financial or non-                           | none |  |
|    | financial interests                               |      |  |
|    |   |      |  |

n/a

Mitund.

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: March 2<sup>nd</sup> 2021

#### Your Name: Paula Ramos Delgado

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution)<br>planning of the work |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | none  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | none  |   |
| 3 | Royalties or licenses  | none  |   |
| 4 | Consulting fees  | none  |   |

| 5  | Payment or honoraria for                        | none |  |
|----|---|------|--|
|    | lectures, presentations,                        |      |  |
|    | speakers bureaus,                               |      |  |
|    | manuscript writing or                           |      |  |
|    | educational events                              |      |  |
| 6  | Payment for expert                              | none |  |
|    | testimony                                       |      |  |
| 7  | Support for attending<br>meetings and/or travel | none |  |
|    |   |      |  |
|    |   |      |  |
| 8  | Patents planned, issued or                      | none |  |
|    | pending   |      |  |
|    |   |      |  |
| 9  | Participation on a Data                         | none |  |
|    | Safety Monitoring Board or                      |      |  |
|    | Advisory Board                                  |      |  |
| 10 | Leadership or fiduciary role                    | none |  |
|    | in other board, society,                        |      |  |
|    | committee or advocacy group, paid or unpaid     |      |  |
| 11 | Stock or stock options                          | none |  |
|    |   |      |  |
|    |   |      |  |
| 12 | Receipt of equipment,                           | none |  |
|    | materials, drugs, medical                       |      |  |
|    | writing, gifts or other                         |      |  |
|    | services  |      |  |
| 13 | Other financial or non-                         | none |  |
|    | financial interests                             |      |  |
|    |   |      |  |

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.



Date:\_March 2<sup>nd</sup> 2021

Your Name: Kathleen Cantow

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|---|--|---|
|   |   | Time frame: Since the initi  | al planning of the work   |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br>No time limit for this item. | German Research<br>Foundation (DFG)  | DFG, Project number 394046635, SFB 1365,<br>RENOPROTECTION                                |
|   |   | Time frame: pas  | st 36 months  |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |

| 4  | Consulting fees  | None |
|----|--|------|
| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |
| 6  | Payment for expert testimony   | None |
| 7  | Support for attending meetings and/or travel   | None |
| 8  | Patents planned, issued or pending   | None |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |
| 11 | Stock or stock options   | None |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |
| 13 | Other financial or non-<br>financial interests   | None |

This work was funded in part (Thoralf Niendorf, Andreas Pohlmann, Thomas Gladytz, Erdmann Seeliger, Sonia Waiczies, Kathleen Cantow) by the German Research Foundation (Gefoerdert durch die Deutsche Forschungsgemeinschaft (DFG), Projektnummer 394046635, SFB 1365, RENOPROTECTION. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project number 394046635, SFB 1365, RENOPROTECTION).

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

- Conter -

Date:\_March 2<sup>nd</sup> 2021

Your Name: Dirk Grosenick

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution)<br>planning of the work |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | none  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | none  |   |
| 3 | Royalties or licenses  | none  |   |
| 4 | Consulting fees  | none  |   |

| 5  | Payment or honoraria for                          | none |  |
|----|---|------|--|
|    | lectures, presentations,                          |      |  |
|    | speakers bureaus,                                 |      |  |
|    | manuscript writing or<br>educational events       |      |  |
| 6  |   |      |  |
| 6  | Payment for expert<br>testimony                   | none |  |
|    | testimony   |      |  |
| 7  | Support for attending                             | none |  |
|    | meetings and/or travel                            |      |  |
|    |   |      |  |
|    |   |      |  |
|    |   |      |  |
| 8  | Patents planned, issued or                        | none |  |
|    | pending   |      |  |
|    |   |      |  |
| 9  | Safety Monitoring Board or                        | none |  |
|    |   |      |  |
| 10 | Advisory Board                                    |      |  |
| 10 |   | none |  |
|    | in other board, society,<br>committee or advocacy |      |  |
|    | group, paid or unpaid                             |      |  |
| 11 | Stock or stock options                            | none |  |
|    |   |      |  |
|    |   |      |  |
| 12 | Receipt of equipment,                             | none |  |
|    | materials, drugs, medical                         |      |  |
|    | writing, gifts or other                           |      |  |
|    | services  |      |  |
| 13 | Other financial or non-                           | none |  |
|    | financial interests                               |      |  |
|    |   |      |  |

n.a.

form.

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

Goosenick

Date: March 2<sup>nd</sup>, 2021 uis Humme Your Name:

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution)<br>planning of the work |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | none  |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | none  |   |
| 3 | Royalties or licenses  | none  |   |
| 4 | Consulting fees  | none  |   |

| 5  | Payment or honoraria for                          | none |  |
|----|---|------|--|
|    | lectures, presentations,                          |      |  |
|    | speakers bureaus,                                 |      |  |
|    | manuscript writing or                             |      |  |
| 6  | educational events                                |      |  |
| 6  | Payment for expert<br>testimony                   | none |  |
|    | testimony   |      |  |
| 7  | Support for attending<br>meetings and/or travel   | none |  |
|    |   |      |  |
|    |   |      |  |
| 8  | Patents planned, issued or                        | none |  |
|    | pending   |      |  |
|    |   |      |  |
| 9  | Participation on a Data                           | none |  |
|    | Safety Monitoring Board or                        |      |  |
| 10 | Advisory Board                                    |      |  |
| 10 | Leadership or fiduciary role                      | none |  |
|    | in other board, society,<br>committee or advocacy |      |  |
|    | group, paid or unpaid                             |      |  |
| 11 | Stock or stock options                            | none |  |
|    |   |      |  |
|    |   |      |  |
| 12 | Receipt of equipment,                             | none |  |
|    | materials, drugs, medical                         |      |  |
|    | writing, gifts or other                           |      |  |
| 13 | services<br>Other financial or non-               | nono |  |
| 13 | financial interests                               | none |  |
|    |   |      |  |
|    |   |      |  |

L certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:\_March 2<sup>nd</sup> 2021

Your Name:\_Ariane Anger

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
| 1 |  | Time frame: Since the initi  | al planning of the work   |
| 1 | All support for the present<br>manuscript (e.g., funding,  | none   |   |
|   | provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br>No time limit for this item. |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: pas  | st 36 months  |
| 2 | Grants or contracts from   | none   |   |
|   | any entity (if not indicated<br>in item #1 above).   |  |   |
| 3 | Royalties or licenses  | none   |   |
|   |  |  |   |
| 4 | Consulting fees  | none   |   |

| 5      | Payment or honoraria for   | 2000 |                      |
|--------|--|------|----------------------|
| 2      | and the second state of the se | none |                      |
|        | lectures, presentations,   |      |                      |
|        | speakers bureaus,  |      |                      |
|        | manuscript writing or  |      |                      |
| certa. | educational events   |      |                      |
| 6      | Payment for expert<br>testimony  | none |                      |
| 7      | Support for attending  | none |                      |
|        | meetings and/or travel   |      |                      |
|        |  |      |                      |
| 8      | Patents planned, issued or   | none |                      |
|        | pending  |      |                      |
| 9      | Participation on a Data  | none |                      |
|        | Safety Monitoring Board or<br>Advisory Board   |      |                      |
| 10     | Leadership or fiduciary role<br>in other board, society,   | none |                      |
|        |  |      |                      |
|        | committee or advocacy group, paid or unpaid  |      | and the state of the |
| 11     | Stock or stock options   | none |                      |
|        |  |      |                      |
| 12     | Receipt of equipment,  | none |                      |
|        | materials, drugs, medical<br>writing, gifts or other<br>services   |      |                      |
| 13     | Other financial or non-  | none |                      |
|        | financial interests  |      |                      |

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:\_March 2<sup>nd</sup> 2021

Your Name:\_

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

XUAN

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)        | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution)  |
|---|--|---|--|
|   |  | Time frame: Since the initi   | al planning of the work  |
| 1 | All support for the present  | none  |  |
|   | manuscript (e.g., funding,   | Service shifts an angela  | the research to available interaction to instance on two   |
|   | provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br>No time limit for this item. |   |  |
|   |  |   |  |
|   |  | Constant of the second of   |  |
|   |  | Time frame: pas   | t 36 months  |
| 2 | Grants or contracts from   | none  |  |
|   | any entity (if not indicated   |   |  |
| - | in item #1 above).   |   |  |
| 3 | Royalties or licenses  | none  |  |
|   | A new la Partie and  | Contraction of the second s |  |
| - | no mousely an to yas to  | A Dec ship is ship we we we   | A District the set of the set |
| 4 | Consulting fees  | none  |  |

|    |  | Autors an Dr                  | COMP TRUNCS  |
|----|--|-------------------------------|--|
| 5  | Payment or honoraria for   | none                          |  |
|    | lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events               | CAA                           | WAUX IAN   |
| 6  | Payment for expert testimony   | none                          | asseque reade contempore participation spectral of the first of the first of the sector System |
| 7  | Support for attending<br>meetings and/or travel  | none                          | 6351-55-2550 Invest® Station Street  |
|    | mainstruction butter deserv  | and gaption and gap damatical | Generation of voy data and principality in paradal   |
| 8  | Patents planned, issued or<br>pending  | none                          |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | none                          | nethor/activity/intervent. If & antisection that you do  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | none                          | mentert onlik.<br>National to a fact with the fact that for the second of the s                |
| 11 | Stock or stock options   | none                          |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | none                          |  |
| 13 | Other financial or non-<br>financial interests   | none                          |  |

I have no actual or potential conflict of interest in relation to this manuscript

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Sp 31 ms

Date: March 4, 2021 Your Name: Erdmann Seeliger Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System Manuscript number (if known): QIMS - 20 - 1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|---|--|---|
|   |   | Time frame: Since the initi  | al planning of the work   |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br>No time limit for this item. | German Research<br>Foundation (DFG)  | DFG, Project number 394046635, SFB 1365,<br>RENOPROTECTION                                |
|   |   | Time frame: pas  | st 36 months  |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |
| 4 | Consulting fees   | None   |   |
| 5 | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events  | None   |   |

| 6  | Payment for expert testimony   | None |
|----|--|------|
|    |  |      |
| 7  | Support for attending meetings and/or travel   | None |
| 8  | Patents planned, issued or pending   | None |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |
| 11 | Stock or stock options   | None |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |
| 13 | Other financial or non-<br>financial interests   | None |

This work was funded in part (Thoralf Niendorf, Andreas Pohlmann, Thomas Gladytz, Erdmann Seeliger, Sonia Waiczies, Kathleen Cantow) by the German Research Foundation (Gefoerdert durch die Deutsche Forschungsgemeinschaft (DFG), Projektnummer 394046635, SFB 1365, RENOPROTECTION. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project number 394046635, SFB 1365, RENOPROTECTION).

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date:\_March 2<sup>nd</sup> 2021

Your Name: Andreas Pohlmann

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initi  | al planning of the work   |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | German Research<br>Foundation (DFG)  | DFG, Project number 394046635, SFB 1365,<br>RENOPROTECTION                                |
|   |  | Time frame: pas  | st 36 months  |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | none   |   |
| 3 | Royalties or licenses  | none   |   |

| 4  | Consulting from  | Added Advent   |
|----|--|--|
| 4  | Consulting fees  | none   |
| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | none and a second secon |
|    |  |  |
| 6  | Payment for expert testimony   | none   |
| 7  | Support for attending meetings and/or travel   | none   |
| 8  | Patents planned, issued or pending   | none   |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | none   |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | none   |
| 11 | Stock or stock options   | none   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | none   |
| 13 | Other financial or non-<br>financial interests   | none e e e e e e e e e e e e e e e e e e   |

This work was funded in part (Thoralf Niendorf, Andreas Pohlmann, Thomas Gladytz, Erdmann Seeliger, Sonia Waiczies, Kathleen Cantow) by the German Research Foundation (Gefoerdert durch die Deutsche Forschungsgemeinschaft (DFG), Projektnummer 394046635, SFB 1365, RENOPROTECTION. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project number 394046635, SFB 1365, RENOPROTECTION).

X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:\_March 2<sup>nd</sup> 2021

Your Name: Sonia Waiczies

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution)<br>planning of the work |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | German Research<br>Foundation (DFG)   | DFG, Project number 394046635, SFB 1365,<br>RENOPROTECTION  |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | none  |   |
| 3 | Royalties or licenses  | none  |   |

| 4  | Consulting fees                                    | none |  |
|----|--|------|--|
|    |  |      |  |
| 5  | Payment or honoraria for                           | none |  |
|    | lectures, presentations,                           |      |  |
|    | speakers bureaus,                                  |      |  |
|    | manuscript writing or                              |      |  |
|    | educational events                                 |      |  |
| 6  | Payment for expert                                 | none |  |
|    | testimony  |      |  |
| 7  | Support for attending<br>meetings and/or travel    | none |  |
|    |  |      |  |
|    |  |      |  |
| 8  | Patents planned, issued or                         | none |  |
|    | pending  |      |  |
|    |  |      |  |
| 9  | Participation on a Data                            | none |  |
|    | Safety Monitoring Board or                         |      |  |
|    | Advisory Board                                     |      |  |
| 10 | Leadership or fiduciary role                       | none |  |
|    | in other board, society,                           |      |  |
|    | committee or advocacy                              |      |  |
|    | group, paid or unpaid                              |      |  |
| 11 | Stock or stock options                             | none |  |
|    |  |      |  |
| 12 | Receipt of equipment                               | nono |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical | none |  |
|    | writing, gifts or other                            |      |  |
|    | services   |      |  |
| 13 | Other financial or non-                            | none |  |
|    | financial interests                                |      |  |
|    |  |      |  |

This work was funded in part (Thoralf Niendorf, Andreas Pohlmann, Thomas Gladytz, Erdmann Seeliger, Sonia Waiczies, Kathleen Cantow) by the German Research Foundation (Gefoerdert durch die Deutsche Forschungsgemeinschaft (DFG), Projektnummer 394046635, SFB 1365, RENOPROTECTION. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project number 394046635, SFB 1365, RENOPROTECTION).

es

X\_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:\_March 2<sup>nd</sup> 2021

Your Name: Thoralf Niendorf

Manuscript Title: Continuous Diffusion Spectrum Computation for Diffusion Weighted Magnetic Resonance Imaging of the Kidney Tubule System

Manuscript number (if known): QIMS-20-1360

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution)                                 |  |  |
|---|--|---|---|--|--|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | German Research<br>Foundation   | Grant funding provided by the German Research<br>Foundation (DFG, Project number 394046635, SFB<br>1365, RENOPROTECTION). |  |  |
|   | Time frame: past 36 months   |   |   |  |  |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | one   |   |  |  |
| 3 | Royalties or licenses  | none  |   |  |  |
| 4 | Consulting fees  | none  |   |  |  |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events<br>Payment for expert<br>testimony | none                               |                              |
|----|---|------------------------------------|------------------------------|
| 7  | Support for attending meetings and/or travel  | none                               |                              |
| 8  | Patents planned, issued or<br>pending   | none                               |                              |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board   | none                               |                              |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid  | none                               |                              |
| 11 | Stock or stock options  | none                               |                              |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services   | none                               |                              |
| 13 | Other financial or non-<br>financial interests  | MRI.TOOLS GmbH, Berlin.<br>Germany | Founder, shareholder and CEO |

Grant funding provided by the German Research Foundation (DFG, Project number 394046635, SFB 1365, **RENOPROTECTION).** 

Founder, shareholder and CEO, MRI.TOOLS GmbH, Berlin. Germany

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form. Teny if